Ausgabe 4/2016
Inhalt (18 Artikel)
NAFLD as a risk factor for HCC: new rules of engagement?
Ryota Masuzaki, Seth J. Karp, Masao Omata
New therapeutic targets in alcoholic hepatitis
Diana Arsene, Omar Farooq, Ramon Bataller
Biliary complications in right lobe living donor liver transplantation
Kenneth S. H. Chok, Chung Mau Lo
Hepatitis B virus receptors and molecular drug targets
Eloi R. Verrier, Che C. Colpitts, Camille Sureau, Thomas F. Baumert
Prevention of hepatitis B virus-associated liver diseases by antiviral therapy
Akinobu Tawada, Tatsuo Kanda, Fumio Imazeki, Osamu Yokosuka
The dynamic changes of circulating invariant natural killer T cells during chronic hepatitis B virus infection
Man Li, Zhen-Hua Zhou, Xue-Hua Sun, Xin Zhang, Xiao-Jun Zhu, Shu-Gen Jin, Yun Jiang, Ya-Ting Gao, Cheng-Zhong Li, Yue-Qiu Gao
Will a second biopsy sample affect treatment decisions in patients with chronic hepatitis B?
Fuat Ekiz, İlhami Yuksel, Ata Turker Arikök, Baris Yilmaz, Akif Altinbas, Bora Aktas, Murat Deveci, Omer Basar, Sahin Coban, Osman Yuksel
Association between hepatitis B virus basal core promoter/precore region mutations and the risk of hepatitis B-related acute-on-chronic liver failure in the Chinese population: an updated meta-analysis
Xueyuan Nian, Zhihui Xu, Yan Liu, Jianhong Chen, Xiaodong Li, Dongping Xu
Examining the clinical course of genotype 1 chronic hepatitis C patients treated with the cosmos regimen: including patients with advanced liver disease and East Asian ancestry
Marina Roytman, Resham Ramkissoon, Christina Wu, Leena Hong, Ruby Trujillo, Leslie Huddleston, Peter Poerzgen, Todd Seto, Linda Wong, Naoky Tsai
Is response guided therapy dead? Low cure rates in patients with detectable hepatitis C virus at week 4 of treatment
Karla Thornton, Paulina Deming, Richard A. Manch, Ann Moore, Anita Kohli, Robert Gish, Norman L. Sussman, Saira Khaderi, John Scott, Jorge Mera, Terry Box, Clifford Qualls, Miranda Sedillo, Sanjeev Arora
Characterization of hepatocellular carcinoma (HCC) in non-alcoholic fatty liver disease (NAFLD) patients without cirrhosis
Bashar Mohamad, Vaishal Shah, Mykola Onyshchenko, Mohammed Elshamy, Federico Aucejo, Rocio Lopez, Ibrahim A. Hanouneh, Razan Alhaddad, Naim Alkhouri
An improved strategy to detect the epithelial-mesenchymal transition process in circulating tumor cells in hepatocellular carcinoma patients
Yong-kang Liu, Bao-shan Hu, Zhong-liang Li, Xu He, Yong Li, Li-gong Lu
Impact of circulating miR-122 for histological features and hepatocellular carcinoma of nonalcoholic fatty liver disease in Japan
Norio Akuta, Yusuke Kawamura, Fumitaka Suzuki, Satoshi Saitoh, Yasuji Arase, Hideo Kunimoto, Yushi Sorin, Shunichiro Fujiyama, Hitomi Sezaki, Tetsuya Hosaka, Masahiro Kobayashi, Yoshiyuki Suzuki, Mariko Kobayashi, Kenji Ikeda, Hiromitsu Kumada
Selection and outcome of the potential live liver donor
Viniyendra Pamecha, Shyam Sunder Mahansaria, Kishore G. S. Bharathy, Senthil Kumar, Shridhar Vasantrao Sasturkar, Piyush Kumar Sinha, Shiv Kumar Sarin
Role of cytokine gene polymorphisms in acute and chronic kidney disease following liver transplantation
Hideya Kamei, Yasuharu Onishi, Taro Nakamura, Masatoshi Ishigami, Nobuyuki Hamajima
Difference in clinical presentation, immunology profile and treatment response of type 1 autoimmune hepatitis between United Kingdom and Singapore patients
Nwe Ni Than, Doreen Koay Siew Ching, James Hodson, Patrick McDowell, Jake Mann, Ravi Gupta, Ennaliza Salazar, Jing Hieng Ngu, Ye Htun Oo